Payment overview · 2025
General Payments
$68.15
4 reported records · 3 companies
Healthcare provider profile · identity verified
Thomas Rayford Blackledge, MD
Allopathic & Osteopathic Physicians|Family Medicine · BILOXI, MS · NPI 1497798615
Verified facts
What the public records show
CMS Open Payments records show Thomas Rayford Blackledge, MD received $68.15 in general payments during 2025 across 4 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 58.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Paxlovid.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.64 | 58.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.50 | 21.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.01 | 20.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $68.15 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 384 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 88 |
| Atorvastatin Calcium | Atorvastatin Calcium | 197 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 187 | 50 |
| Metformin Hcl Er | Metformin Hcl | 174 | 61 |
| Famotidine | Famotidine | 165 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 154 | 38 |
| Gabapentin | Gabapentin | 153 | 41 |
| Montelukast Sodium | Montelukast Sodium | 128 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 40 |
| Metformin Hcl | Metformin Hcl | 124 | 42 |
| Azithromycin | Azithromycin | 122 | 100 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 34 |
| Tramadol Hcl | Tramadol Hcl | 113 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 34 |
| Lisinopril | Lisinopril | 102 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 94 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 25 |
| Bupropion Xl | Bupropion Hcl | 84 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 18 |
| Furosemide | Furosemide | 80 | 33 |
| Sucralfate | Sucralfate | 78 | 21 |
| Potassium Chloride | Potassium Chloride | 74 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 22 |
| Meloxicam | Meloxicam | 65 | 17 |
| Prednisone | Prednisone | 65 | 53 |
| Carvedilol | Carvedilol | 62 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 13 |
| Simvastatin | Simvastatin | 54 | 16 |
| Trazodone Hcl | Trazodone Hcl | 51 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 16 |
| Eliquis | Apixaban | 45 | 14 |
| Omeprazole | Omeprazole | 45 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 38 |
| Sertraline Hcl | Sertraline Hcl | 41 | 13 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 36 | 23 |
| Alendronate Sodium | Alendronate Sodium | 34 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 13 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Estradiol | Estradiol | 32 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Glipizide | Glipizide | 31 | 11 |
| Ozempic | Semaglutide | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | 15 |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | 11 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $68.15 · 4 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, JARDIANCE, PAXLOVID | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error